Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
177Lu-PSMA-617 + niraparib + abiraterone acetate + prednisone
- Development stage
- Unknown
- Lead developer
- Baptist Health South Florida
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This investigational combination therapy is being evaluated in the Phase 1/2 LUNAAR trial (NCT05567952) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The regimen integrates three distinct therapeutic modalities: radioligand therapy with 177Lu-PSMA-617 (Pluvicto), which delivers targeted beta-particle radiation to cells expressing prostate-specific membrane antigen (PSMA); PARP inhibition with niraparib, which disrupts DNA repair mechanisms; and androgen biosynthesis inhibition with abiraterone acetate (administered as a fixed-dose combination with niraparib, known as Akeega). Prednisone is included to manage the mineralocorticoid effects of abiraterone. This multi-pronged approach aims to enhance anti-tumor activity by combining targeted radiation with the inhibition of DNA damage response and androgen receptor signaling pathways. The study is sponsored by Baptist Health South Florida.
- Brand names
- Akeega
- Other names
- Lutetium Lu 177 vipivotide tetraxetan + niraparib + abiraterone acetate + prednisone177Lu-PSMA-617 + Niraparib/Abiraterone + Prednisone
02
Targets
CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)GR (Glucocorticoid receptor)PARP1 (Poly (adp-ribose) polymerase 1)Pol II (RNA polymerase II elongation factors)PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 177Lu-PSMA-617 + niraparib + abiraterone acetate + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 177Lu-PSMA-617 + niraparib + abiraterone acetate + prednisone.